Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Globe Newswire News Releases

Apr 24, 2024 16:05 ET
Black Diamond Therapeutics Announces Presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced forthcoming presentations during the 2024 ASCO...
Apr 24, 2024 16:05 ET
Cidara Therapeutics Reacquires Global Development and Commercial Rights to CD388 and Announces Private Placement Financing of $240 Million
Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious...
Apr 24, 2024 16:05 ET
ClearPoint Neuro Announces Initiation of Limited Market Release for the SmartFrame OR™ Stereotactic System
ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced it has initiated the Limited Market Release for its SmartFrame OR™...
Apr 24, 2024 16:05 ET
Covenant Logistics Group Announces First Quarter Financial and Operating Results
Covenant Logistics Group, Inc. (NASDAQ/GS: CVLG) (“Covenant” or the “Company”) announced today financial and operating results for the first quarter ended March 31, 2024. The Company’s conference call to discuss the quarter will be held at 10:00...
Apr 24, 2024 16:05 ET
Eagle Bancorp, Inc. Announces Results of Operations for First Quarter 2024
Eagle Bancorp, Inc. (the "Company") (NASDAQ: EGBN), the parent company of EagleBank (the "Bank"), today announced a net loss of $338 thousand for the first quarter 2024, compared to net income of $20.2 million for the fourth quarter 2023 (the...
Apr 24, 2024 16:05 ET
Ethan Allen Reports Fiscal 2024 Third Quarter Results Highlighted by Robust Balance Sheet, Strong Cash Dividends and Double-Digit Operating Margin; Lower Demand Reflects Post Pandemic Period
Ethan Allen Interiors Inc. (“Ethan Allen” or the “Company”) (NYSE: ETD), a leading interior design destination, today reported its financial and operating results for the fiscal 2024 third quarter ended March 31, 2024. Farooq Kathwari, Ethan...
Apr 24, 2024 16:05 ET
FNCB Bancorp, Inc. Declares Second Quarter 2024 Dividend
On April 24, 2024, the Board of Directors of FNCB Bancorp, Inc. (NASDAQ:FNCB) declared a dividend of $0.090 per share for the second quarter of 2024. The second quarter 2024 dividend is payable on June 17, 2024 to shareholders of record as of June...
Apr 24, 2024 16:05 ET
Mama’s Creations Reports Fourth Quarter and Fiscal Year 2024 Financial Results
Mama’s Creations, Inc. (Nasdaq: MAMA), a leading national marketer and manufacturer of fresh deli prepared foods, has reported its financial results for fourth quarter and fiscal year ended January 31, 2024. Financial Summary:   Three Months...
Apr 24, 2024 16:05 ET
Nasdaq Announces Mid-Month Open Short Interest Positions in Nasdaq Stocks as of Settlement Date April 15, 2024
At the end of the settlement date of April 15, 2024, short interest in 3,081 Nasdaq Global MarketSM securities totaled 11,407,213,969 shares compared with 11,297,406,980 shares in 3,102 Global Market issues reported for the prior settlement date of...
Apr 24, 2024 16:05 ET
Venus Concept Announces Loan Purchase and Completion of First Phase of Refinancing
Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that on April 23, 2024, its existing Main Street Lending Program Loan (“MSLP Loan”) was purchased by affiliates of...
Apr 24, 2024 16:02 ET
Churchill Downs Incorporated Reports 2024 First Quarter Results
Churchill Downs Incorporated (Nasdaq: CHDN) (the "Company", "CDI", "we") today reported business results for the first quarter ended March 31, 2024. Company Highlights First quarter results: Record net revenue of $590.9 million, up 6% compared to...
Apr 24, 2024 16:02 ET
FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Prese
FibroGen, Inc. (NASDAQ: FGEN) today announced that clinical data from the dose escalation portion of the Phase 1b/2 study of FG-3246 in combination with enzalutamide in patients with metastatic castration resistant prostate cancer have been...
Apr 24, 2024 16:02 ET
Finward Bancorp Announces Earnings for the Quarter Ended March 31, 2024
Finward Bancorp (Nasdaq: FNWD) (the “Bancorp”), the holding company for Peoples Bank (the “Bank”), today announced that net income available to common stockholders was $9.3 million, or $2.17 per diluted share, for the quarter ended March 31, 2024,...
Apr 24, 2024 16:01 ET
Great Lakes Announces New $150,000,000 Second-Lien Financing Agreement
Great Lakes Dredge & Dock Corporation ("Great Lakes" or the “Company”) (NASDAQ: GLDD), the largest provider of dredging services in the United States, announced that it has entered into a $150,000,000 5-year, senior secured second-lien credit...
Apr 24, 2024 16:01 ET
Capital Southwest Announces Fourth Quarter and Fiscal Year 2024 Earnings Release and Conference Call Schedule
Capital Southwest Corporation (“Capital Southwest” or the “Company”; Nasdaq: CSWC), an internally managed business development company focused on providing flexible financing solutions to support the acquisition and growth of middle market...
Apr 24, 2024 16:01 ET
Cidara Therapeutics Announces Divestiture of Rezafungin to Mundipharma* to Focus on Advancing the Clinical Development of Cloudbreak DFC Pipeline
Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious...
Apr 24, 2024 16:01 ET
Iovance Biotherapeutics to Present Clinical and Translational Data at 2024 ASCO Annual Meeting
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today...
Apr 24, 2024 16:01 ET
Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that it will present a study update of the oral CDK9 inhibitor KB-0742 in relapsed or refractory transcriptionally addicted...
Apr 24, 2024 16:00 ET
Cytokinetics to Announce First Quarter Results on May 8, 2024
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report first quarter results on May 8, 2024 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management will host a conference call at 4:30...
Apr 24, 2024 16:00 ET
Freeline to Present New Data on its Gaucher and Parkinson’s Disease Programs at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
Freeline Therapeutics today announced the acceptance of multiple abstracts, including one for a late-breaking oral presentation on new clinical data from its Gaucher disease program, at the upcoming American Society of Gene and Cell Therapy (ASGCT)...